Doctor Thomas Mondritzki
Bayer AG, Wuppertal (Germany)
Preclinical evaluation of a novel dual acting V1a/V2 vasopressin receptor antagonist by using a noninvasive cardiac output monitor
Event: Heart Failure 2018
Topic: Experimental Heart Failure
Session: Chronic Heart Failure – Pathophysiology and Mechanisms
Dual V1a/V2 versus selective V2 vasopressin receptor blockade in a preclinical heart failure model: does it matter?
Event: ESC Congress 2016
Topic: Pharmacologic therapy
Session: Heart failure / Left ventricular dysfunction
ESC 365 is supported by
